> Detailanzeige

van Campenhout, Margo J. H.; Brouwer, Willem Pieter; Xie, Qing; Guo, S.; Chi, Heng; Qi, Xun; Tabak, Fehmi; Streinu‐Cercel, Adrian; Wang, Ji‐Yao; Zhang, Ning‐Ping; Idilman, Ramazan; Reesink, Hendrik W.; Diculescu, Mircea; Simon, Krzysztof; Akdogan, Meral; Mazur, Włodzimierz; de Knegt, Rob J.; Verhey, Elke; Hansen, Bettina E.; Janssen, Harry L. A.

Long‐term follow‐up of patients treated with entecavir and peginterferon add‐on therapy for HBeAg‐positive chronic hepatitis B infection: ARES long‐term follow‐up

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Long‐term follow‐up of patients treated with entecavir and peginterferon add‐on therapy for HBeAg‐positive chronic hepatitis B infection: ARES long‐term follow‐up
  • Beteiligte: van Campenhout, Margo J. H.; Brouwer, Willem Pieter; Xie, Qing; Guo, S.; Chi, Heng; Qi, Xun; Tabak, Fehmi; Streinu‐Cercel, Adrian; Wang, Ji‐Yao; Zhang, Ning‐Ping; Idilman, Ramazan; Reesink, Hendrik W.; Diculescu, Mircea; Simon, Krzysztof; Akdogan, Meral; Mazur, Włodzimierz; de Knegt, Rob J.; Verhey, Elke; Hansen, Bettina E.; Janssen, Harry L. A.
  • Erschienen: Wiley, 2019
  • Erschienen in: Journal of Viral Hepatitis, 26 (2019) 1, Seite 109-117
  • Sprache: Englisch
  • DOI: 10.1111/jvh.12997
  • ISSN: 1352-0504; 1365-2893
  • Schlagwörter: Virology ; Infectious Diseases ; Hepatology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Summary</jats:title><jats:p>Addition of peginterferon alpha (<jats:styled-content style="fixed-case">PEG</jats:styled-content>‐<jats:styled-content style="fixed-case">IFN</jats:styled-content> add‐on) to entecavir (<jats:styled-content style="fixed-case">ETV</jats:styled-content>) treatment after a short lead‐in phase results in more response than <jats:styled-content style="fixed-case">ETV</jats:styled-content> monotherapy in <jats:styled-content style="fixed-case">HB</jats:styled-content>eAg‐positive chronic hepatitis B infection (<jats:styled-content style="fixed-case">CHB</jats:styled-content>). This study is the first to assess long‐term efficacy of this treatment strategy. Patients who received <jats:styled-content style="fixed-case">ETV</jats:styled-content> ± 24 weeks of <jats:styled-content style="fixed-case">PEG</jats:styled-content>‐<jats:styled-content style="fixed-case">IFN</jats:styled-content> add‐on in a global trial (<jats:styled-content style="fixed-case">ARES</jats:styled-content> study) and completed follow‐up were eligible to participate in this observational <jats:styled-content style="fixed-case">LTFU</jats:styled-content> study if they had at least one combined <jats:styled-content style="fixed-case">HB</jats:styled-content>eAg and <jats:styled-content style="fixed-case">HBV DNA</jats:styled-content> measurement beyond week 96 of the <jats:styled-content style="fixed-case">ARES</jats:styled-content> study. The primary endpoint was combined response (<jats:styled-content style="fixed-case">HB</jats:styled-content>eAg loss and <jats:styled-content style="fixed-case">HBV DNA</jats:styled-content> &lt;200 <jats:styled-content style="fixed-case">IU</jats:styled-content>/<jats:styled-content style="fixed-case">mL</jats:styled-content>) at <jats:styled-content style="fixed-case">LTFU</jats:styled-content>. In total, 48 patients treated with <jats:styled-content style="fixed-case">PEG</jats:styled-content>‐<jats:styled-content style="fixed-case">IFN</jats:styled-content> add‐on and 48 patients treated with <jats:styled-content style="fixed-case">ETV</jats:styled-content> monotherapy were included. The median follow‐up duration was 226 (<jats:styled-content style="fixed-case">IQR</jats:styled-content> 51) weeks, and 86/96 (90%) patients were initial non‐responders. At <jats:styled-content style="fixed-case">LTFU</jats:styled-content>, combined response was present in 13 (27%) vs 11 (23%) patients (<jats:italic>P</jats:italic> = 0.81), and 1 log<jats:sub>10</jats:sub> <jats:styled-content style="fixed-case">HB</jats:styled-content>sAg decline in 59% vs 28% (<jats:italic>P</jats:italic> = 0.02) for <jats:styled-content style="fixed-case">PEG</jats:styled-content>‐<jats:styled-content style="fixed-case">IFN</jats:styled-content> add‐on and <jats:styled-content style="fixed-case">ETV</jats:styled-content> monotherapy, respectively. In 41 initial non‐responders who continued <jats:styled-content style="fixed-case">ETV</jats:styled-content> therapy, combined response at <jats:styled-content style="fixed-case">LTFU</jats:styled-content> was present in 9 patients (<jats:styled-content style="fixed-case">PEG</jats:styled-content>‐<jats:styled-content style="fixed-case">IFN</jats:styled-content> add‐on: 5/22 [23%]; <jats:styled-content style="fixed-case">ETV</jats:styled-content> monotherapy: 4/19 [21%]). Beyond week 96 of follow‐up, rates of serological response became comparable between <jats:styled-content style="fixed-case">PEG</jats:styled-content>‐<jats:styled-content style="fixed-case">IFN</jats:styled-content> add‐on and <jats:styled-content style="fixed-case">ETV</jats:styled-content> monotherapy. Although in this <jats:styled-content style="fixed-case">LTFU</jats:styled-content> study initial non‐responders were overrepresented in the add‐on arm, <jats:styled-content style="fixed-case">PEG</jats:styled-content>‐<jats:styled-content style="fixed-case">IFN</jats:styled-content> add‐on possibly leads rather to accelerated <jats:styled-content style="fixed-case">HB</jats:styled-content>eAg loss than to increased long‐term <jats:styled-content style="fixed-case">HB</jats:styled-content>eAg loss rates.</jats:p>